News >

TP53 Variants Increase Risk for Pediatric ALL, Adverse Treatment Outcomes

Jason Harris
Published: Friday, Jan 12, 2018

Jun J. Yang, PhD
Jun J. Yang, PhD
Children with TP53 pathogenic variants were more likely to both develop acute lymphoblastic leukemia (ALL), as well as secondary cancers later on, according to an analysis of 3801 Children with newly diagnosed B-cell ALL enrolled in 2 consecutive Children’s Oncology Group trials.

= .9).
Qian M, Cao X, Devidas M, et al. TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children [published online January 4, 2018]. J Clin Oncol doi: 10.1200/JCO.2017.75.5215.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication